Tier 2 — strong

Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects

S-Y Wang, K-M Duan, Y Li, Y Mei, H Sheng, H Liu, X Mei, W Ouyang, H-H Zhou, Z-Q Liu
European journal of clinical nutrition 2013 67(4):390

Bibliography

PubMed
PMID 23422925
DOI
10.1038/ejcn.2013.5
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized open-label two-period crossover interaction study
ModelHuman intervention research
Sample18 healthy volunteers; 165 people were screened for genotype
InterventionQuercetin 500 mg/day for 13 days, followed by talinolol 100 mg
DurationTwo periods separated by a 28-day washout
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2013, this source examined safety, interactions and special populations. Design: Randomized open-label two-period crossover interaction study. Sample/model: 18 healthy volunteers; 165 people were screened for genotype. The exposure or intervention was Quercetin 500 mg/day for 13 days, followed by talinolol 100 mg. Follow-up or treatment period: Two periods separated by a 28-day washout.

Quercetin reduced talinolol exposure and peak concentration, with differences by MDR1 genotype.

The trial sample was 18, not the 165 screened. Results are specific to the drug, schedule, and genotypes studied and cannot establish universal transporter inhibition.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Side Effects and Safety: A Practical Guide. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin reduced talinolol exposure and peak concentration, with differences by MDR1 genotype.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 mg/day for 13 days, followed by talinolol 100 mg; Two periods separated by a 28-day washout.

What this study can and cannot tell us

  • The trial sample was 18, not the 165 screened. Results are specific to the drug, schedule, and genotypes studied and cannot establish universal transporter inhibition.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology